nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—SLC19A1—mammary gland—sarcoma	0.0387	0.0904	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Vincristine—sarcoma	0.0253	0.0527	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Mitoxantrone—sarcoma	0.0246	0.0513	CcSEcCtD
Pralatrexate—SLC19A1—hematopoietic system—sarcoma	0.0236	0.0551	CbGeAlD
Pralatrexate—FPGS—myometrium—sarcoma	0.0183	0.0427	CbGeAlD
Pralatrexate—SLC19A1—lymphoid tissue—sarcoma	0.0166	0.0388	CbGeAlD
Pralatrexate—FPGS—seminal vesicle—sarcoma	0.0165	0.0386	CbGeAlD
Pralatrexate—FPGS—hematopoietic system—sarcoma	0.0157	0.0367	CbGeAlD
Pralatrexate—FPGS—connective tissue—sarcoma	0.0151	0.0353	CbGeAlD
Pralatrexate—FPGS—skin of body—sarcoma	0.0136	0.0319	CbGeAlD
Pralatrexate—SLC19A1—testis—sarcoma	0.0129	0.0302	CbGeAlD
Pralatrexate—SLC19A1—liver—sarcoma	0.0122	0.0285	CbGeAlD
Pralatrexate—FPGS—cardiac atrium—sarcoma	0.0119	0.0279	CbGeAlD
Pralatrexate—DHFR—myometrium—sarcoma	0.0119	0.0278	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Epirubicin—sarcoma	0.0115	0.0239	CcSEcCtD
Pralatrexate—DHFR—embryo—sarcoma	0.0114	0.0267	CbGeAlD
Pralatrexate—FPGS—lymphoid tissue—sarcoma	0.0111	0.0258	CbGeAlD
Pralatrexate—DHFR—seminal vesicle—sarcoma	0.0107	0.0251	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Doxorubicin—sarcoma	0.0106	0.0221	CcSEcCtD
Pralatrexate—FPGS—tendon—sarcoma	0.0104	0.0243	CbGeAlD
Pralatrexate—TYMS—hematopoietic system—sarcoma	0.0103	0.0241	CbGeAlD
Pralatrexate—DHFR—hematopoietic system—sarcoma	0.0102	0.0238	CbGeAlD
Pralatrexate—TYMS—connective tissue—sarcoma	0.00991	0.0232	CbGeAlD
Pralatrexate—DHFR—connective tissue—sarcoma	0.00982	0.023	CbGeAlD
Pralatrexate—SLC19A1—lymph node—sarcoma	0.00936	0.0219	CbGeAlD
Pralatrexate—Neoplasm malignant—Thiotepa—sarcoma	0.00927	0.0193	CcSEcCtD
Pralatrexate—TYMS—smooth muscle tissue—sarcoma	0.00907	0.0212	CbGeAlD
Pralatrexate—TYMS—skin of body—sarcoma	0.00895	0.0209	CbGeAlD
Pralatrexate—TYMS—Vinorelbine—Vincristine—sarcoma	0.00862	0.372	CbGdCrCtD
Pralatrexate—TYMS—Podofilox—Etoposide—sarcoma	0.00861	0.372	CbGdCrCtD
Pralatrexate—FPGS—testis—sarcoma	0.0086	0.0201	CbGeAlD
Pralatrexate—FPGS—liver—sarcoma	0.00813	0.019	CbGeAlD
Pralatrexate—FPGS—Fluoropyrimidine Activity—SMUG1—sarcoma	0.00808	0.117	CbGpPWpGaD
Pralatrexate—DHFR—cardiac atrium—sarcoma	0.00774	0.0181	CbGeAlD
Pralatrexate—DHFR—uterus—sarcoma	0.0077	0.018	CbGeAlD
Pralatrexate—TYMS—lymphoid tissue—sarcoma	0.00725	0.0169	CbGeAlD
Pralatrexate—DHFR—lymphoid tissue—sarcoma	0.00718	0.0168	CbGeAlD
Pralatrexate—SLC19A1—Folate Metabolism—HBA1—sarcoma	0.00695	0.1	CbGpPWpGaD
Pralatrexate—Sepsis—Thiotepa—sarcoma	0.00687	0.0143	CcSEcCtD
Pralatrexate—Sepsis—Dactinomycin—sarcoma	0.00682	0.0142	CcSEcCtD
Pralatrexate—TYMS—tendon—sarcoma	0.00682	0.0159	CbGeAlD
Pralatrexate—DHFR—tendon—sarcoma	0.00675	0.0158	CbGeAlD
Pralatrexate—TYMS—bone marrow—sarcoma	0.0066	0.0154	CbGeAlD
Pralatrexate—DHFR—bone marrow—sarcoma	0.00654	0.0153	CbGeAlD
Pralatrexate—FPGS—lymph node—sarcoma	0.00624	0.0146	CbGeAlD
Pralatrexate—Sepsis—Mitoxantrone—sarcoma	0.00593	0.0124	CcSEcCtD
Pralatrexate—TYMS—Vinblastine—Vincristine—sarcoma	0.00593	0.256	CbGdCrCtD
Pralatrexate—TYMS—testis—sarcoma	0.00564	0.0132	CbGeAlD
Pralatrexate—DHFR—testis—sarcoma	0.00559	0.0131	CbGeAlD
Pralatrexate—Dehydration—Thiotepa—sarcoma	0.00534	0.0111	CcSEcCtD
Pralatrexate—TYMS—liver—sarcoma	0.00534	0.0125	CbGeAlD
Pralatrexate—DHFR—liver—sarcoma	0.00528	0.0123	CbGeAlD
Pralatrexate—Liver function test abnormal—Dactinomycin—sarcoma	0.00526	0.011	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.00513	0.0107	CcSEcCtD
Pralatrexate—Pain in extremity—Vincristine—sarcoma	0.00509	0.0106	CcSEcCtD
Pralatrexate—Sepsis—Etoposide—sarcoma	0.00493	0.0103	CcSEcCtD
Pralatrexate—Dehydration—Vincristine—sarcoma	0.00474	0.00987	CcSEcCtD
Pralatrexate—Pancytopenia—Thiotepa—sarcoma	0.00472	0.00982	CcSEcCtD
Pralatrexate—Pancytopenia—Dactinomycin—sarcoma	0.00468	0.00975	CcSEcCtD
Pralatrexate—Dehydration—Mitoxantrone—sarcoma	0.00461	0.00961	CcSEcCtD
Pralatrexate—Neutropenia—Dactinomycin—sarcoma	0.00461	0.0096	CcSEcCtD
Pralatrexate—Hypokalaemia—Mitoxantrone—sarcoma	0.00452	0.00941	CcSEcCtD
Pralatrexate—Pancytopenia—Vincristine—sarcoma	0.00418	0.00871	CcSEcCtD
Pralatrexate—Epistaxis—Thiotepa—sarcoma	0.00418	0.0087	CcSEcCtD
Pralatrexate—Neutropenia—Vincristine—sarcoma	0.00412	0.00858	CcSEcCtD
Pralatrexate—TYMS—lymph node—sarcoma	0.00409	0.00956	CbGeAlD
Pralatrexate—Pancytopenia—Mitoxantrone—sarcoma	0.00407	0.00848	CcSEcCtD
Pralatrexate—DHFR—lymph node—sarcoma	0.00405	0.00947	CbGeAlD
Pralatrexate—Neutropenia—Mitoxantrone—sarcoma	0.00401	0.00835	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Mitoxantrone—sarcoma	0.00399	0.0083	CcSEcCtD
Pralatrexate—Neoplasm malignant—Epirubicin—sarcoma	0.00373	0.00778	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Etoposide—sarcoma	0.00372	0.00774	CcSEcCtD
Pralatrexate—Neoplasm malignant—Doxorubicin—sarcoma	0.00345	0.00719	CcSEcCtD
Pralatrexate—Pancytopenia—Etoposide—sarcoma	0.00339	0.00706	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—SMUG1—sarcoma	0.00338	0.0488	CbGpPWpGaD
Pralatrexate—Back pain—Thiotepa—sarcoma	0.00335	0.00697	CcSEcCtD
Pralatrexate—Neutropenia—Etoposide—sarcoma	0.00334	0.00695	CcSEcCtD
Pralatrexate—Anaemia—Thiotepa—sarcoma	0.0032	0.00666	CcSEcCtD
Pralatrexate—Anaemia—Dactinomycin—sarcoma	0.00317	0.00661	CcSEcCtD
Pralatrexate—Leukopenia—Thiotepa—sarcoma	0.0031	0.00645	CcSEcCtD
Pralatrexate—Leukopenia—Dactinomycin—sarcoma	0.00307	0.0064	CcSEcCtD
Pralatrexate—Cough—Thiotepa—sarcoma	0.00302	0.00629	CcSEcCtD
Pralatrexate—Back pain—Vincristine—sarcoma	0.00297	0.00618	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—SMUG1—sarcoma	0.00295	0.0426	CbGpPWpGaD
Pralatrexate—Back pain—Mitoxantrone—sarcoma	0.00289	0.00602	CcSEcCtD
Pralatrexate—Anaemia—Vincristine—sarcoma	0.00284	0.00591	CcSEcCtD
Pralatrexate—Oedema—Dactinomycin—sarcoma	0.0028	0.00584	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—sarcoma	0.00277	0.00576	CcSEcCtD
Pralatrexate—Thrombocytopenia—Thiotepa—sarcoma	0.00276	0.00576	CcSEcCtD
Pralatrexate—Anaemia—Mitoxantrone—sarcoma	0.00276	0.00575	CcSEcCtD
Pralatrexate—Tachycardia—Thiotepa—sarcoma	0.00276	0.00574	CcSEcCtD
Pralatrexate—Leukopenia—Vincristine—sarcoma	0.00275	0.00572	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dactinomycin—sarcoma	0.00274	0.00572	CcSEcCtD
Pralatrexate—Anorexia—Thiotepa—sarcoma	0.00269	0.00561	CcSEcCtD
Pralatrexate—Leukopenia—Mitoxantrone—sarcoma	0.00267	0.00557	CcSEcCtD
Pralatrexate—Anorexia—Dactinomycin—sarcoma	0.00267	0.00557	CcSEcCtD
Pralatrexate—Cough—Mitoxantrone—sarcoma	0.00261	0.00543	CcSEcCtD
Pralatrexate—Sepsis—Doxorubicin—sarcoma	0.00256	0.00533	CcSEcCtD
Pralatrexate—Oedema—Vincristine—sarcoma	0.0025	0.00522	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—HBA1—sarcoma	0.00247	0.0357	CbGpPWpGaD
Pralatrexate—Decreased appetite—Thiotepa—sarcoma	0.00245	0.00511	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vincristine—sarcoma	0.00245	0.00511	CcSEcCtD
Pralatrexate—Oedema—Mitoxantrone—sarcoma	0.00244	0.00508	CcSEcCtD
Pralatrexate—Decreased appetite—Dactinomycin—sarcoma	0.00244	0.00508	CcSEcCtD
Pralatrexate—Fatigue—Thiotepa—sarcoma	0.00243	0.00507	CcSEcCtD
Pralatrexate—Fatigue—Dactinomycin—sarcoma	0.00242	0.00503	CcSEcCtD
Pralatrexate—Constipation—Thiotepa—sarcoma	0.00241	0.00503	CcSEcCtD
Pralatrexate—Back pain—Etoposide—sarcoma	0.0024	0.00501	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mitoxantrone—sarcoma	0.00239	0.00497	CcSEcCtD
Pralatrexate—Anorexia—Vincristine—sarcoma	0.00239	0.00497	CcSEcCtD
Pralatrexate—Tachycardia—Mitoxantrone—sarcoma	0.00238	0.00496	CcSEcCtD
Pralatrexate—Anorexia—Mitoxantrone—sarcoma	0.00232	0.00484	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—sarcoma	0.00231	0.00482	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Thiotepa—sarcoma	0.00231	0.00481	CcSEcCtD
Pralatrexate—Anaemia—Etoposide—sarcoma	0.0023	0.00479	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dactinomycin—sarcoma	0.00229	0.00477	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—IL2—sarcoma	0.00226	0.0326	CbGpPWpGaD
Pralatrexate—Abdominal pain—Thiotepa—sarcoma	0.00223	0.00465	CcSEcCtD
Pralatrexate—Body temperature increased—Thiotepa—sarcoma	0.00223	0.00465	CcSEcCtD
Pralatrexate—Leukopenia—Etoposide—sarcoma	0.00222	0.00463	CcSEcCtD
Pralatrexate—Body temperature increased—Dactinomycin—sarcoma	0.00222	0.00462	CcSEcCtD
Pralatrexate—Abdominal pain—Dactinomycin—sarcoma	0.00222	0.00462	CcSEcCtD
Pralatrexate—Decreased appetite—Vincristine—sarcoma	0.00218	0.00453	CcSEcCtD
Pralatrexate—Dyspnoea—Mitoxantrone—sarcoma	0.00217	0.00453	CcSEcCtD
Pralatrexate—Cough—Etoposide—sarcoma	0.00217	0.00452	CcSEcCtD
Pralatrexate—Fatigue—Vincristine—sarcoma	0.00216	0.0045	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—sarcoma	0.00215	0.00448	CcSEcCtD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—sarcoma	0.00215	0.031	CbGpPWpGaD
Pralatrexate—Constipation—Vincristine—sarcoma	0.00214	0.00446	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—sarcoma	0.00214	0.00446	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—sarcoma	0.00214	0.00445	CcSEcCtD
Pralatrexate—Decreased appetite—Mitoxantrone—sarcoma	0.00212	0.00442	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—sarcoma	0.00211	0.00439	CcSEcCtD
Pralatrexate—Fatigue—Mitoxantrone—sarcoma	0.0021	0.00438	CcSEcCtD
Pralatrexate—Constipation—Mitoxantrone—sarcoma	0.00209	0.00434	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.00208	0.00434	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vincristine—sarcoma	0.00205	0.00427	CcSEcCtD
Pralatrexate—Asthenia—Thiotepa—sarcoma	0.00203	0.00422	CcSEcCtD
Pralatrexate—Asthenia—Dactinomycin—sarcoma	0.00201	0.00419	CcSEcCtD
Pralatrexate—Pruritus—Thiotepa—sarcoma	0.002	0.00416	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00199	0.00415	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—sarcoma	0.00199	0.00415	CcSEcCtD
Pralatrexate—Thrombocytopenia—Etoposide—sarcoma	0.00199	0.00414	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—sarcoma	0.00198	0.00412	CcSEcCtD
Pralatrexate—Abdominal pain—Vincristine—sarcoma	0.00198	0.00412	CcSEcCtD
Pralatrexate—Body temperature increased—Vincristine—sarcoma	0.00198	0.00412	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—sarcoma	0.00198	0.00412	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—sarcoma	0.00195	0.00406	CcSEcCtD
Pralatrexate—Anorexia—Etoposide—sarcoma	0.00193	0.00403	CcSEcCtD
Pralatrexate—Diarrhoea—Thiotepa—sarcoma	0.00193	0.00403	CcSEcCtD
Pralatrexate—Body temperature increased—Mitoxantrone—sarcoma	0.00193	0.00402	CcSEcCtD
Pralatrexate—Abdominal pain—Mitoxantrone—sarcoma	0.00193	0.00402	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.00193	0.00402	CcSEcCtD
Pralatrexate—Diarrhoea—Dactinomycin—sarcoma	0.00192	0.004	CcSEcCtD
Pralatrexate—Pancytopenia—Epirubicin—sarcoma	0.0019	0.00396	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—sarcoma	0.00187	0.0039	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—sarcoma	0.00186	0.00387	CcSEcCtD
Pralatrexate—Dyspnoea—Etoposide—sarcoma	0.00181	0.00377	CcSEcCtD
Pralatrexate—Asthenia—Vincristine—sarcoma	0.0018	0.00374	CcSEcCtD
Pralatrexate—Vomiting—Thiotepa—sarcoma	0.0018	0.00374	CcSEcCtD
Pralatrexate—Vomiting—Dactinomycin—sarcoma	0.00178	0.00371	CcSEcCtD
Pralatrexate—Rash—Thiotepa—sarcoma	0.00178	0.00371	CcSEcCtD
Pralatrexate—Dermatitis—Thiotepa—sarcoma	0.00178	0.00371	CcSEcCtD
Pralatrexate—Rash—Dactinomycin—sarcoma	0.00177	0.00368	CcSEcCtD
Pralatrexate—Decreased appetite—Etoposide—sarcoma	0.00176	0.00367	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—sarcoma	0.00176	0.00366	CcSEcCtD
Pralatrexate—Asthenia—Mitoxantrone—sarcoma	0.00175	0.00365	CcSEcCtD
Pralatrexate—Fatigue—Etoposide—sarcoma	0.00175	0.00364	CcSEcCtD
Pralatrexate—Constipation—Etoposide—sarcoma	0.00173	0.00361	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—sarcoma	0.00173	0.0036	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—sarcoma	0.00172	0.00358	CcSEcCtD
Pralatrexate—Diarrhoea—Vincristine—sarcoma	0.00171	0.00357	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—sarcoma	0.00168	0.0035	CcSEcCtD
Pralatrexate—Nausea—Thiotepa—sarcoma	0.00168	0.00349	CcSEcCtD
Pralatrexate—Diarrhoea—Mitoxantrone—sarcoma	0.00167	0.00348	CcSEcCtD
Pralatrexate—Nausea—Dactinomycin—sarcoma	0.00166	0.00347	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Etoposide—sarcoma	0.00166	0.00346	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—sarcoma	0.0016	0.00334	CcSEcCtD
Pralatrexate—Body temperature increased—Etoposide—sarcoma	0.0016	0.00334	CcSEcCtD
Pralatrexate—Vomiting—Vincristine—sarcoma	0.00159	0.00332	CcSEcCtD
Pralatrexate—Rash—Vincristine—sarcoma	0.00158	0.00329	CcSEcCtD
Pralatrexate—Dermatitis—Vincristine—sarcoma	0.00158	0.00329	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—sarcoma	0.00156	0.00324	CcSEcCtD
Pralatrexate—Vomiting—Mitoxantrone—sarcoma	0.00155	0.00323	CcSEcCtD
Pralatrexate—Rash—Mitoxantrone—sarcoma	0.00154	0.0032	CcSEcCtD
Pralatrexate—Dermatitis—Mitoxantrone—sarcoma	0.00154	0.0032	CcSEcCtD
Pralatrexate—Nausea—Vincristine—sarcoma	0.00149	0.0031	CcSEcCtD
Pralatrexate—Asthenia—Etoposide—sarcoma	0.00146	0.00303	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—sarcoma	0.00145	0.021	CbGpPWpGaD
Pralatrexate—Nausea—Mitoxantrone—sarcoma	0.00145	0.00302	CcSEcCtD
Pralatrexate—Pruritus—Etoposide—sarcoma	0.00144	0.00299	CcSEcCtD
Pralatrexate—Diarrhoea—Etoposide—sarcoma	0.00139	0.00289	CcSEcCtD
Pralatrexate—Back pain—Epirubicin—sarcoma	0.00135	0.00281	CcSEcCtD
Pralatrexate—Vomiting—Etoposide—sarcoma	0.00129	0.00269	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—sarcoma	0.00129	0.00268	CcSEcCtD
Pralatrexate—Rash—Etoposide—sarcoma	0.00128	0.00266	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—sarcoma	0.00128	0.00266	CcSEcCtD
Pralatrexate—Leukopenia—Epirubicin—sarcoma	0.00125	0.0026	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—sarcoma	0.00125	0.0026	CcSEcCtD
Pralatrexate—Cough—Epirubicin—sarcoma	0.00122	0.00253	CcSEcCtD
Pralatrexate—Nausea—Etoposide—sarcoma	0.0012	0.00251	CcSEcCtD
Pralatrexate—Anaemia—Doxorubicin—sarcoma	0.00119	0.00248	CcSEcCtD
Pralatrexate—Leukopenia—Doxorubicin—sarcoma	0.00115	0.0024	CcSEcCtD
Pralatrexate—Oedema—Epirubicin—sarcoma	0.00114	0.00237	CcSEcCtD
Pralatrexate—Cough—Doxorubicin—sarcoma	0.00112	0.00234	CcSEcCtD
Pralatrexate—Thrombocytopenia—Epirubicin—sarcoma	0.00111	0.00232	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—sarcoma	0.00111	0.00231	CcSEcCtD
Pralatrexate—Anorexia—Epirubicin—sarcoma	0.00108	0.00226	CcSEcCtD
Pralatrexate—Oedema—Doxorubicin—sarcoma	0.00105	0.00219	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.00103	0.0149	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—sarcoma	0.00103	0.00215	CcSEcCtD
Pralatrexate—Tachycardia—Doxorubicin—sarcoma	0.00103	0.00214	CcSEcCtD
Pralatrexate—Dyspnoea—Epirubicin—sarcoma	0.00101	0.00211	CcSEcCtD
Pralatrexate—Anorexia—Doxorubicin—sarcoma	0.001	0.00209	CcSEcCtD
Pralatrexate—Decreased appetite—Epirubicin—sarcoma	0.000988	0.00206	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—sarcoma	0.00098	0.00204	CcSEcCtD
Pralatrexate—Constipation—Epirubicin—sarcoma	0.000972	0.00203	CcSEcCtD
Pralatrexate—Dyspnoea—Doxorubicin—sarcoma	0.000938	0.00195	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Epirubicin—sarcoma	0.00093	0.00194	CcSEcCtD
Pralatrexate—Decreased appetite—Doxorubicin—sarcoma	0.000915	0.00191	CcSEcCtD
Pralatrexate—Fatigue—Doxorubicin—sarcoma	0.000907	0.00189	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—sarcoma	0.0009	0.00187	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—sarcoma	0.000899	0.00187	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—sarcoma	0.000899	0.00187	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—sarcoma	0.000896	0.013	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—sarcoma	0.00086	0.00179	CcSEcCtD
Pralatrexate—SLC19A1—Disease—TLE1—sarcoma	0.000849	0.0123	CbGpPWpGaD
Pralatrexate—Abdominal pain—Doxorubicin—sarcoma	0.000832	0.00173	CcSEcCtD
Pralatrexate—Body temperature increased—Doxorubicin—sarcoma	0.000832	0.00173	CcSEcCtD
Pralatrexate—Asthenia—Epirubicin—sarcoma	0.000816	0.0017	CcSEcCtD
Pralatrexate—Pruritus—Epirubicin—sarcoma	0.000804	0.00168	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—IL2—sarcoma	0.000802	0.0116	CbGpPWpGaD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—sarcoma	0.000782	0.0113	CbGpPWpGaD
Pralatrexate—Diarrhoea—Epirubicin—sarcoma	0.000778	0.00162	CcSEcCtD
Pralatrexate—SLC19A1—Disease—NPM1—sarcoma	0.000766	0.0111	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—sarcoma	0.000755	0.00157	CcSEcCtD
Pralatrexate—Pruritus—Doxorubicin—sarcoma	0.000744	0.00155	CcSEcCtD
Pralatrexate—Vomiting—Epirubicin—sarcoma	0.000723	0.00151	CcSEcCtD
Pralatrexate—FPGS—Disease—TLE1—sarcoma	0.000722	0.0104	CbGpPWpGaD
Pralatrexate—Diarrhoea—Doxorubicin—sarcoma	0.00072	0.0015	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000719	0.0104	CbGpPWpGaD
Pralatrexate—Rash—Epirubicin—sarcoma	0.000717	0.00149	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—sarcoma	0.000716	0.00149	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—STAG1—sarcoma	0.000691	0.00999	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—sarcoma	0.000675	0.00141	CcSEcCtD
Pralatrexate—Vomiting—Doxorubicin—sarcoma	0.000669	0.00139	CcSEcCtD
Pralatrexate—SLC19A1—Disease—ENO2—sarcoma	0.000664	0.00959	CbGpPWpGaD
Pralatrexate—Rash—Doxorubicin—sarcoma	0.000663	0.00138	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—sarcoma	0.000663	0.00138	CcSEcCtD
Pralatrexate—FPGS—Disease—NPM1—sarcoma	0.000651	0.00942	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	0.000628	0.00907	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000627	0.00906	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—sarcoma	0.000625	0.0013	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—STAG1—sarcoma	0.000618	0.00894	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—STAG1—sarcoma	0.000603	0.00872	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—MYC—sarcoma	0.000578	0.00836	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ENO2—sarcoma	0.000564	0.00816	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PLCG1—sarcoma	0.000563	0.00814	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ENO2—sarcoma	0.000556	0.00803	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—HBA1—sarcoma	0.000552	0.00798	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000548	0.00792	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	0.000547	0.0079	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CXCR4—sarcoma	0.000541	0.00782	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—STAG1—sarcoma	0.000539	0.0078	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—NPM1—sarcoma	0.00053	0.00767	CbGpPWpGaD
Pralatrexate—DHFR—Folate Metabolism—TP53—sarcoma	0.000515	0.00744	CbGpPWpGaD
Pralatrexate—TYMS—E2F transcription factor network—MYC—sarcoma	0.000505	0.0073	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000503	0.00727	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PLCG1—sarcoma	0.000479	0.00692	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ENO2—sarcoma	0.000472	0.00683	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PLCG1—sarcoma	0.000471	0.00682	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—HBA1—sarcoma	0.00047	0.00679	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—NPM1—sarcoma	0.000463	0.00669	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CXCR4—sarcoma	0.00046	0.00665	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—sarcoma	0.000441	0.00637	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—sarcoma	0.000439	0.00634	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—MYC—sarcoma	0.00042	0.00607	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.000413	0.00597	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000404	0.00585	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PLCG1—sarcoma	0.000401	0.0058	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—FOXO1—sarcoma	0.000399	0.00578	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PDGFRB—sarcoma	0.000399	0.00577	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PDGFRA—sarcoma	0.000393	0.00568	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—CREB1—sarcoma	0.000388	0.00561	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—sarcoma	0.000385	0.00556	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—sarcoma	0.000366	0.00529	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—sarcoma	0.00036	0.00521	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—sarcoma	0.000354	0.00511	CbGpPWpGaD
Pralatrexate—FPGS—Disease—FOXO1—sarcoma	0.00034	0.00491	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PDGFRB—sarcoma	0.000339	0.0049	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000335	0.00484	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PDGFRA—sarcoma	0.000334	0.00483	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—sarcoma	0.000309	0.00446	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KIT—sarcoma	0.000304	0.0044	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TLE1—sarcoma	0.000302	0.00436	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000291	0.00421	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000291	0.0042	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CREB1—sarcoma	0.00029	0.00419	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000289	0.00417	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—JUN—sarcoma	0.000279	0.00404	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NPM1—sarcoma	0.000272	0.00393	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000261	0.00377	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KIT—sarcoma	0.000259	0.00374	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000254	0.00367	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CREB1—sarcoma	0.000246	0.00356	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MDM2—sarcoma	0.00024	0.00347	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ENO2—sarcoma	0.000236	0.00341	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000234	0.00338	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000229	0.00331	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000216	0.00312	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—sarcoma	0.000207	0.00299	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MDM2—sarcoma	0.000204	0.00295	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PLCG1—sarcoma	0.0002	0.00289	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ENO2—sarcoma	0.000197	0.00285	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—HBA1—sarcoma	0.000196	0.00284	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CXCR4—sarcoma	0.000192	0.00278	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	0.000192	0.00278	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SRC—sarcoma	0.000187	0.0027	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—sarcoma	0.000184	0.00266	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—sarcoma	0.00018	0.0026	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—sarcoma	0.000176	0.00254	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ENO2—sarcoma	0.000172	0.00249	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—HBA1—sarcoma	0.000171	0.00247	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—sarcoma	0.000167	0.00242	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PLCG1—sarcoma	0.000167	0.00242	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MDM2—sarcoma	0.000166	0.0024	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—sarcoma	0.000164	0.00237	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—sarcoma	0.000162	0.00234	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SRC—sarcoma	0.000159	0.0023	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—sarcoma	0.000155	0.00224	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—sarcoma	0.000153	0.00221	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PLCG1—sarcoma	0.000146	0.00211	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MDM2—sarcoma	0.000145	0.00209	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—sarcoma	0.000145	0.00209	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—sarcoma	0.000142	0.00206	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FOXO1—sarcoma	0.000142	0.00205	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PDGFRB—sarcoma	0.000142	0.00205	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—sarcoma	0.000141	0.00204	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PDGFRA—sarcoma	0.000139	0.00202	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—sarcoma	0.000139	0.00201	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—sarcoma	0.000132	0.0019	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—sarcoma	0.000132	0.0019	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—sarcoma	0.00013	0.00188	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—sarcoma	0.000126	0.00182	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—sarcoma	0.000116	0.00168	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—sarcoma	0.000113	0.00164	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—sarcoma	0.000112	0.00162	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KIT—sarcoma	0.000108	0.00156	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CREB1—sarcoma	0.000103	0.00149	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—sarcoma	0.000101	0.00146	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—sarcoma	9.52e-05	0.00138	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MDM2—sarcoma	8.51e-05	0.00123	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—sarcoma	8.31e-05	0.0012	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—sarcoma	7.34e-05	0.00106	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SRC—sarcoma	6.64e-05	0.00096	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—sarcoma	6.39e-05	0.000923	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—sarcoma	5.95e-05	0.00086	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—sarcoma	5.82e-05	0.000841	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—sarcoma	5.5e-05	0.000795	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—sarcoma	4.67e-05	0.000676	CbGpPWpGaD
